Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02176356
Other study ID # GMA-CMB-14-001
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 30, 2014
Est. completion date May 3, 2015

Study information

Verified date December 2018
Source Allergan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study to evaluate patient satisfaction, aesthetic and psychological impact of combined treatment with BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC, and LATISSE® (bimatoprost ophthalmic solution).


Recruitment information / eligibility

Status Completed
Enrollment 116
Est. completion date May 3, 2015
Est. primary completion date May 3, 2015
Accepts healthy volunteers No
Gender All
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria:

- Qualified to receive treatment with BOTOX® Cosmetic, a facial filler (JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA Plus XC and/or JUVÉDERM® VOLUMA® XC) and LATISSE® treatment

- Naïve to botulinum toxin therapy of any serotype for any indication

- Naïve to prescription eyelash growth products of any type

- Naïve to dermal filler treatment in the face and neck

Exclusion Criteria:

- Undergone facial plastic surgery, tissue grafting, tissue augmentation or facial dermal filler injections

- Had laser, photomodulation, intense pulsed light, radio frequency, dermabrasion or chemical peel in the face or neck

- Have received skin resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or non-ablative procedures) in the face or neck within 3 months

- Systemic retinoid therapy within 1 year prior to study enrollment

- Presence of inflammation at the proposed injection site(s)

- Profound atrophy/excessive weakness of muscles in target areas of injection

- Known immunization or hypersensitivity to any botulinum toxin serotype

- Undergone oral surgery or dental procedures within 30 days

- No visible eyelashes

- Use of permanent eyeliner, eyelash implants, semi-permanent eyelash tint, dye or extension

- Use of prescription eyelash growth products

- Unwilling or unable to remove contact lenses prior to study medication application in the evening and keep lenses out for 30 minutes

- Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, amyotrophic lateral sclerosis, or any other disease that might interfere with neuromuscular function.

Study Design


Intervention

Biological:
onabotulinumtoxinA
onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
Drug:
bimatoprost ophthalmic solution 0.03%
bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
Device:
JUVÉDERM® ULTRA XC
JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
JUVÉDERM® ULTRA PLUS XC
JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
JUVÉDERM® VOLUMA® XC
JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Allergan

Country where clinical trial is conducted

United States, 

References & Publications (1)

Weinkle SH, Werschler WP, Teller CF, Sykes JM, Shamban A, Rivkin A, Narurkar VA, Kaminer MS, Dayan S, Cohen JL, Gallagher CJ. Impact of Comprehensive, Minimally Invasive, Multimodal Aesthetic Treatment on Satisfaction With Facial Appearance: The HARMONY Study. Aesthet Surg J. 2018 Apr 6;38(5):540-556. doi: 10.1093/asj/sjx179. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Satisfaction With Facial Appearance Overall Using a 10-item Questionnaire Participants assessed their satisfaction with the way they look right now with their entire face in mind using a 10-item questionnaire. Possible responses to each question were: 1=Very dissatisfied, 2=Somewhat dissatisfied, 3-=Somewhat satisfied and 4=Very satisfied. The responses were added across items and transformed to a Rasch scale ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement. Baseline, Month 4
Secondary Change From Baseline in Aging Appearance Using a 7-item Questionnaire Participants rated how they look now using a 7-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4=Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement. Baseline, Month 4
Secondary Change From Baseline in Age Appraisal Using a Visual Analogue Scale (VAS) Participants assessed how old they think they look compared to their actual age using a VAS by placing a mark on a number on a horizontal line where the far left of the line= -15 (look 15 years younger), 0=look current age, to the far right of the line=15 (look 15 years older). A positive change from Baseline indicates improvement. Baseline, Month 4
Secondary Change From Baseline in Social Confidence Using an 8-item Questionnaire Participants assessed their social confidence with their facial appearance in mind in the past week using an 8-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement. Baseline, Month 4
Secondary Change From Baseline in Psychological Well-Being Using a 10-item Questionnaire Participants assessed their psychological well-being with their facial appearance in mind using a 10-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement. Baseline, Month 4
Secondary Participant's Self- Perception of Age (SPA) Participants assessed SPA by answering the question: How do you think your facial appearance looks compared to your age today? Participants recorded how many years younger or older they thought their facial appearance made them look. A negative result indicates improvement (a younger appearance). Baseline, Month 4
Secondary Change From Baseline in Investigator's Assessment of Severity of Glabellar Lines (GLs) at Maximum Frown Using the Facial Wrinkle Scale (FWS) The investigator assessed the severity of the participant's GLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement. Baseline, Month 4
Secondary Change From Baseline in Investigator's Assessment of the Severity of Crow's Feet Lines (CFLs) at Maximum Smile Using the FWS The investigator assessed the severity of the participant's CFLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement. Baseline, Month 4
Secondary Change From Baseline in Investigator's Global Eyelash Assessment Score (GEAS) The investigator assessed the participant's eyelash prominence using the 4-point GEAS where: 1=Minimal (worst), 2=Moderate, 3=Marked and 4=Very Marked (best). A positive change from Baseline indicates improvement. Baseline, Month 4
Secondary Change From Baseline in the Investigator's Assessment of the Participant's Overall Mid-Face Volume Deficit Using the 6-Point MFVDS The investigator assessed overall mid-face volume deficit using the Mid-face Volume Deficit Scale (MFVDS) where: 0=None (moon face; fullness) [best], 1=Minimal (flattening), 2=Mild (mild concavity), 3=Moderate (moderate concavity, 4=Significant (significant concavity) and 5=Severe (wasting) [worst]. A negative change from Baseline indicates improvement. Baseline, Month 4
Secondary Change From Baseline in the Investigator's Assessment of the Participant's Nasolabial Folds Severity The investigator assessed the participants nasolabial folds severity using the 5-Point Nasolabial Fold Severity (NLFS) Scale where: 0=None (no wrinkles) [best], 1=Mild (shallow, just perceptible wrinkle), 2=Moderate (moderately deep wrinkle), 3=Severe (deep wrinkle) or 4= Extreme (very deep wrinkle). A negative change from Baseline indicates improvement. Baseline, Month 4
Secondary Change From Baseline in the Investigator's Assessment of the Participant's Oral Commissures Severity The investigator assessed the participant's oral commissure using the 4-Point Oral Commissure Severity Scale (OCSS) where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement. Baseline, Month 4
Secondary Change From Baseline in the Investigator's Assessment of the Participant's Perioral Lines Severity The investigator assessed the participant's perioral lines severity using the 4-Point Perioral Lines at Rest Severity Scale (POLSS) where: 0=None (no lines) [best], 1=Mild (few, shallow lines), 2=Moderate (some moderate lines) or 3=Severe (many deep lines or crevices)[worst]. A negative change from Baseline indicates improvement. Baseline, Month 4
Secondary Change From Baseline in the Participant Satisfaction With Appearance of Periorbital Area Participants assessed how their overall eye appearance has affected them over the past 7 days using the 9-item Periorbital Aesthetic Appearance Questionnaire (PAAQ). Possible responses to each question were: 0=Never (best), 1=Rarely, 2=Some of the time, 3=Most of the time and 4=All of the time with a total possible score of 0 to 36. A negative change from Baseline indicates improvement. Baseline, Month 4
See also
  Status Clinical Trial Phase
Completed NCT04096326 - AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines Phase 2
Completed NCT02961673 - The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines Phase 1/Phase 2
Completed NCT01271452 - Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines Phase 4
Completed NCT05013424 - A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines Phase 2
Completed NCT01189760 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines Phase 3
Completed NCT05100199 - A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines Phase 2
Completed NCT03721016 - MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) Phase 3
Completed NCT04157686 - MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) Phase 3
Completed NCT02353897 - Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
Completed NCT03732833 - MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines Phase 3
Completed NCT06212960 - Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines Phase 1
Completed NCT05089357 - Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
Completed NCT00408785 - A Study Of BOTOX For The Treatment Of Glabellar Lines Phase 3
Completed NCT05380154 - Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines. Phase 3
Completed NCT01224015 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines Phase 3
Completed NCT05248880 - A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines Phase 3
Completed NCT03216408 - Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines Phase 3
Recruiting NCT06308198 - A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines Phase 3
Completed NCT05298449 - Phase 2 of HU-045 in Glabellar Lines Phase 2
Not yet recruiting NCT06246552 - Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines Phase 2